L. Mofenson

发表

O222 Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trial

C. Giaquinto, F. Monpoux, D. Nadal, 2008 .

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

S. Gortmaker, E. Moore, L. Mofenson, 1999, JAMA.

Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings

D. Harris, J. Moye, J. Korelitz, 2003, The Lancet.

Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

L. Mofenson, J. Moye, R. Nugent, 1993, Journal of acquired immune deficiency syndromes.

Determinations of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma: Reassessment of Parameters Affecting Assay Outcome

T. Quinn, L. Mofenson, M. Robb, 1998, Journal of Clinical Microbiology.

Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus‐infected children

L. Mofenson, J. Moye, R. Nugent, 1994, The Pediatric infectious disease journal.

Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

J. Moye, R. Nugent, J. Bethel, 1992, JAMA.

A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus

L. Mofenson, L. Mofenson, 1995, The Pediatric infectious disease journal.

Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions

L. Mofenson, 1997, Acta paediatrica (Oslo, Norway : 1992). Supplement.

RISK FACTORS FOR PERINATAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN WOMEN TREATED WITH ZIDOVUDINE

D. Harris, J. Lambert, L. Mofenson, 1999 .

Reducing the risk of perinatal HIV‐1 transmission with zidovudine: results and implications of AIDS Clinical Trials Group protocol 076

L. Mofenson, 1997, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Perinatal Human Immunodeficiency Virus (HIV) Testing

S. Schonberg, R. Pantell, A. Fleischman, 1992, Pediatrics.

Impact of GB virus type C infection on mother‐to‐child HIV transmission in the Women and Infants Transmission Study Cohort

R. Hershow, E. Handelsman, F. Hollinger, 2007, HIV medicine.

Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children

M. Hughes, D. Harris, C. Giaquinto, 2010, AIDS.

Response to planned treatment interruptions in HIV infection varies across childhood

J. Ananworanich, J. Darbyshire, F. Monpoux, 2010, AIDS.

The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

J. Moye, R. Nugent, J. Korelitz, 1997, The Journal of infectious diseases.

Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

S. Pelton, J. Moye, R. Nugent, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pediatric AIDS: Clinical, Pathologic, and Basic Science Perspectives. Conference proceedings. Washington, D.C., November 18-21, 1992.

Boechat, R. Elashoff, R. Mellins, 1993, Annals of the New York Academy of Sciences.

Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV‐infected Children Participating in an Area‐under‐the‐curve Controlled Trial

L. Mofenson, S. Spector, C. Fletcher, 2008, Clinical pharmacology and therapeutics.

Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

D. Harris, J. Moye, R. Nugent, 1999, AIDS.

Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries.

G. Gottlieb, J. Stringer, C. Yiannoutsos, 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

J. Lambert, M. Fowler, G. Nemo, 1999, The New England journal of medicine.